Bayer Covered Up Yasmin Blood Clot Risk: Ex-FDA Head

Law360, New York (December 5, 2011, 10:54 PM EST) -- Bayer AG hid the significance of potentially serious side effects of its Yasmin contraceptives despite knowing they were more likely to cause blood clots than other oral contraceptives, according to a former U.S. Food and Drug Administration chief's report unsealed Monday in multidistrict litigation in Illinois.

In a 121-page expert report, former FDA Commissioner David Kessler said the drugmaker had documented in the draft of an August 2004 white paper that Yasmin was 10 times more likely to cause serious side effects including deep vein thrombosis,...
To view the full article, register now.

Related

Sections

Case Information

Case Title

In Re: Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation


Case Number

3:09-md-02100

Court

Illinois Southern

Nature of Suit

Personal Inj. Prod. Liability

Judge

David R. Herndon

Date Filed

October 1, 2009

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.